Pipeline

TEC-001

TEC-001 with transarterial embolization (TATE) uses a well-established procedure to shut off blood supply to the tumor to create the hypoxic environment necessary for drug activation. TATE has the potential to enhance the efficacy of FDA-approved immune checkpoint inhibitors (ICIs) and transform the standard of care for patients battling cancer. TEC-001 works with ICIs to generate a systemic anticancer immune response that can target cancer cells throughout the body. This durable anticancer immunity helps safeguard against future cancer growth and promote lasting remission.

TEC-002

Our second pipeline, TEC-002 induces tumor death and presents tumor antigen to the immune system. This process activates the body’s immune system, enabling it to recognize tumors as foreign substances and generate an immune response against them. TEC-002 is designed for use with all solid tumors and is anticipated to have broad applications.

TEC-003

Our third pipeline, TEC-003, is triggered after TEC-001 or TEC-002 treatment by harnessing the physiological immune response. This approach leverages the patient’s own immune system to target tumors, serving as a potent therapeutic strategy to combat cancer. It has the potential to collaboratively target multiple tumor antigens, maximizing its effectiveness.

Our Pipeline

Our approaches promise novel treatments for solid tumors, extending lives and challenge current treatment paradigm for patients who have exhausted treatment options.

Preclinical

Phase 1

Phase 2

Collaborators

TEC-001

+Keytruda

COLORECTAL CANCER

FDA
Meeting

TEC-001

LIVER CANCER

Intermediate stage

FDA
Meeting

TEC-001

+Opdivo

LIVER CANCER

Advanced stage

TEC-001

+Keytruda

LUNG CANCER

TEC-001

+Opdivo

STOMACH CANCER

TEC-001

NEUROENDOCRINE TUMOR

TEC-002

SOLID TUMORS

TEC-003

SOLID TUMORS

Indications

Teclison is preparing to launch its first pipeline product, TATE, for advanced hepatocellular carcinoma (HCC). Currently in phase 2 clinical trials, TATE has shown promising preliminary results in patients with advanced HCC who have not responded to immunotherapy. This result will support advanced HCC as the first indication for TATE. Additionally, phase 2 trials are underway for other cancers, including lung, gastric, colorectal, and neuroendocrine tumors.

Teclison is actively expanding its treatment indications to target a wider range of cancer types with its highly specific, tumor-targeting strategy, providing new hope for patients who have developed resistance to standard treatments.

Targeted future indications